Literature DB >> 28212889

Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells.

R R Massaro1, F Faião-Flores1, V W Rebecca2, S Sandri1, D K Alves-Fernandes1, P C Pennacchi1, K S M Smalley2, S S Maria-Engler3.   

Abstract

Despite the recent advances in the clinical management of melanoma, there remains a need for new pharmacological approaches to treat this cancer. 2-methoxyestradiol (2ME) is a metabolite of estrogen that has shown anti-tumor effects in many cancer types. In this study we show that 2ME treatment leads to growth inhibition in melanoma cells, an effect associated with entry into senescence, decreased pRb and Cyclin B1 expression, increased p21/Cip1 expression and G2/M cell cycle arrest. 2ME treatment also inhibits melanoma cell growth in colony formation assay, including cell lines with acquired resistance to BRAF and BRAF+MEK inhibitors. We further show that 2ME is effective against melanoma with different BRAF and NRAS mutational status. Moreover, 2ME induced the retraction of cytoplasmic projections in a 3D spheroid model and significantly decreased cell proliferation in a 3D skin reconstruct model. Together our studies bring new insights into the mechanism of action of 2ME allowing melanoma targeted therapy to be further refined. Continued progress in this area is expected to lead to improved anti-cancer treatments and the development of new and more effective clinical analogues.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2-methoxyestradiol; Chemoresistance; Estrogen; Melanoma

Mesh:

Substances:

Year:  2017        PMID: 28212889      PMCID: PMC5642284          DOI: 10.1016/j.phrs.2017.02.013

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  43 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Melanoma: new insights and new therapies.

Authors:  Vasiliki A Nikolaou; Alexander J Stratigos; Keith T Flaherty; Hensin Tsao
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

3.  Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.

Authors:  William L Dahut; Nehal J Lakhani; James L Gulley; Philip M Arlen; Elise C Kohn; Herbert Kotz; Debbie McNally; Allyson Parr; Diana Nguyen; Sherry X Yang; Seth M Steinberg; Jürgen Venitz; Alex Sparreboom; William D Figg
Journal:  Cancer Biol Ther       Date:  2006-01-22       Impact factor: 4.742

4.  The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells.

Authors:  S Al-Nasiry; N Geusens; M Hanssens; C Luyten; R Pijnenborg
Journal:  Hum Reprod       Date:  2007-02-16       Impact factor: 6.918

5.  In vitro and in vivo antitumor effect of 2-methoxyestradiol on human melanoma.

Authors:  Judit Dobos; József Tímár; József Bocsi; Zsuzsanna Burián; Katalin Nagy; Gábor Barna; István Peták; Andrea Ladányi
Journal:  Int J Cancer       Date:  2004-12-10       Impact factor: 7.396

Review 6.  Hallmarks of senescence in carcinogenesis and cancer therapy.

Authors:  Jerry W Shay; Igor B Roninson
Journal:  Oncogene       Date:  2004-04-12       Impact factor: 9.867

7.  A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model.

Authors:  Suman Kambhampati; Roger A Rajewski; Mehmet Tanol; Inamul Haque; Amlan Das; Snigdha Banerjee; Saheli Jha; Douglas Burns; Emma Borrego-Diaz; Peter J Van Veldhuizen; Sushanta K Banerjee
Journal:  Mol Cancer Ther       Date:  2013-01-03       Impact factor: 6.261

8.  Understanding melanoma signaling networks as the basis for molecular targeted therapy.

Authors:  Keiran S M Smalley
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

9.  Artificial skin in perspective: concepts and applications.

Authors:  Carla A Brohem; Laura B da Silva Cardeal; Manoela Tiago; María S Soengas; Silvia B de Moraes Barros; Silvya S Maria-Engler
Journal:  Pigment Cell Melanoma Res       Date:  2010-11-09       Impact factor: 4.693

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  7 in total

Review 1.  The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.

Authors:  Mariana Matias; Jacinta O Pinho; Maria João Penetra; Gonçalo Campos; Catarina Pinto Reis; Maria Manuela Gaspar
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

2.  Evaluation of 2-methoxyestradiol serum levels as a potential prognostic marker in malignant melanoma.

Authors:  Igor Hrgovic; Johannes Kleemann; Monika Doll; Carmen Loquai; Florian Weid; Frank Louwen; Nadja Zoeller; Stefan Kippenberger; Roland Kaufmann; Markus Meissner
Journal:  Mol Clin Oncol       Date:  2021-05-23

3.  Lysosomal trapping of palbociclib and its functional implications.

Authors:  Susana Llanos; Diego Megias; Carmen Blanco-Aparicio; Elena Hernández-Encinas; Miguel Rovira; Federico Pietrocola; Manuel Serrano
Journal:  Oncogene       Date:  2019-01-28       Impact factor: 9.867

4.  2-methoxyestradiol sensitizes breast cancer cells to taxanes by targeting centrosomes.

Authors:  Randa El-Zein; Jose Thaiparambil; Sherif Z Abdel-Rahman
Journal:  Oncotarget       Date:  2020-12-01

Review 5.  3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs.

Authors:  Mélanie A G Barbosa; Cristina P R Xavier; Rúben F Pereira; Vilma Petrikaitė; M Helena Vasconcelos
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

6.  A versatile drug delivery system targeting senescent cells.

Authors:  Daniel Muñoz-Espín; Miguel Rovira; Irene Galiana; Cristina Giménez; Beatriz Lozano-Torres; Marta Paez-Ribes; Susana Llanos; Selim Chaib; Maribel Muñoz-Martín; Alvaro C Ucero; Guillermo Garaulet; Francisca Mulero; Stephen G Dann; Todd VanArsdale; David J Shields; Andrea Bernardos; José Ramón Murguía; Ramón Martínez-Máñez; Manuel Serrano
Journal:  EMBO Mol Med       Date:  2018-09       Impact factor: 12.137

7.  2-Methoxyestradiol and Its Combination with a Natural Compound, Ferulic Acid, Induces Melanoma Cell Death via Downregulation of Hsp60 and Hsp90.

Authors:  Anna Kamm; Paulina Przychodzeń; Alicja Kuban-Jankowska; Antonella Marino Gammazza; Francesco Cappello; Agnieszka Daca; Michał A Żmijewski; Michał Woźniak; Magdalena Górska-Ponikowska
Journal:  J Oncol       Date:  2019-10-02       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.